{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:28:40Z","timestamp":1777332520437,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interferon (IFN) exerts its effects through interferon-stimulated genes (ISGs), but its efficacy is limited by interferon resistance, which can be caused by the ubiquitination of key proteins. UBE2O was initially identified as a promising therapeutic target based on data from the TCGA and iUUCD 2.0 databases. Through the inhibition of UBE2O, interferon \u03b1\/\u03b2 signaling and overall interferon signaling were activated. Integrating data from proteomic, mass spectrometry, and survival analyses led to the identification of IFIT3, a mediator of interferon signaling, as a ubiquitination substrate of UBE2O. The results of in vitro and in vivo experiments demonstrated that the knockdown of UBE2O can enhance the efficacy of interferon-\u03b1 by upregulating IFIT3 expression. K236 was identified as a ubiquitination site in IFIT3, and the results of rescue experiments confirmed that the effect of UBE2O on interferon-\u03b1 sensitivity is dependent on IFIT3 activity. ATO treatment inhibited UBE2O and increased IFIT3 expression, thereby increasing the effectiveness of interferon-\u03b1. In conclusion, these findings suggest that UBE2O worsens the therapeutic effect of interferon-\u03b1 by targeting IFIT3 for ubiquitination and degradation.<\/jats:p>","DOI":"10.1038\/s41419-023-06369-9","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T17:02:36Z","timestamp":1703178156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["UBE2O reduces the effectiveness of interferon-\u03b1 via degradation of IFIT3 in hepatocellular carcinoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Heng","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0365-3229","authenticated-orcid":false,"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Hang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong-yin","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Hui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan-Zheng","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-9586","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4578-3817","authenticated-orcid":false,"given":"Jia-Bei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3535-6467","authenticated-orcid":false,"given":"Lian-Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"6369_CR1","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374\u2013403.","journal-title":"Eur J Cancer"},{"key":"6369_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5500\/wjt.v6.i2.306","volume":"6","author":"TJ Byrne","year":"2016","unstructured":"Byrne TJ, Rakela J. Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: selecting an optimal therapy. World J Transplant. 2016;6:306\u201313.","journal-title":"World J Transplant"},{"key":"6369_CR3","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1158\/2159-8290.CD-22-0472","volume":"12","author":"KC Kao","year":"2022","unstructured":"Kao KC, Jaccard A, Ho PC. IFNalpha potentiates immune-checkpoint blockade by rewiring metabolic cross-talk. Cancer Discov. 2022;12:1615\u20136.","journal-title":"Cancer Discov"},{"key":"6369_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41416-018-0352-y","volume":"120","author":"H Ma","year":"2019","unstructured":"Ma H, Yang W, Zhang L, Liu S, Zhao M, Zhou G, et al. Interferon-alpha promotes immunosuppression through IFNAR1\/STAT1 signalling in head and neck squamous cell carcinoma. Br J Cancer. 2019;120:317\u201330.","journal-title":"Br J Cancer"},{"key":"6369_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167:1540\u201354.e12.","journal-title":"Cell"},{"key":"6369_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","volume":"18","author":"EC Borden","year":"2019","unstructured":"Borden EC. Interferons alpha and beta in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov. 2019;18:219\u201334.","journal-title":"Nat Rev Drug Discov"},{"key":"6369_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.it.2015.01.004","volume":"36","author":"HH Hoffmann","year":"2015","unstructured":"Hoffmann HH, Schneider WM, Rice CM. Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol. 2015;36:124\u201338.","journal-title":"Trends Immunol"},{"key":"6369_CR8","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.it.2017.05.005","volume":"38","author":"LM Snell","year":"2017","unstructured":"Snell LM, McGaha TL, Brooks DG. Type I interferon in chronic virus infection and cancer. Trends Immunol. 2017;38:542\u201357.","journal-title":"Trends Immunol"},{"key":"6369_CR9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","volume":"50","author":"HM Lazear","year":"2019","unstructured":"Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type I and type III interferons. Immunity. 2019;50:907\u201323.","journal-title":"Immunity"},{"key":"6369_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/hep.29156","volume":"66","author":"Y Yang","year":"2017","unstructured":"Yang Y, Zhou Y, Hou J, Bai C, Li Z, Fan J, et al. Hepatic IFIT3 predicts interferon-alpha therapeutic response in patients of hepatocellular carcinoma. Hepatology. 2017;66:152\u201366.","journal-title":"Hepatology"},{"key":"6369_CR11","doi-asserted-by":"publisher","first-page":"100663","DOI":"10.1016\/j.drup.2019.100663","volume":"48","author":"S Narayanan","year":"2020","unstructured":"Narayanan S, Cai CY, Assaraf YG, Guo HQ, Cui Q, Wei L, et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat. 2020;48:100663.","journal-title":"Drug Resist Updat"},{"key":"6369_CR12","first-page":"168","volume":"41","author":"D Hormaechea-Agulla","year":"2018","unstructured":"Hormaechea-Agulla D, Kim Y, Song MS, Song SJ. New insights into the role of E2s in the pathogenesis of diseases: lessons learned from UBE2O. Mol Cells. 2018;41:168\u201378.","journal-title":"Mol Cells"},{"key":"6369_CR13","doi-asserted-by":"publisher","first-page":"188679","DOI":"10.1016\/j.bbcan.2022.188679","volume":"1877","author":"SC Chang","year":"2022","unstructured":"Chang SC, Zhang BX, Ding JL. E2-E3 ubiquitin enzyme pairing - partnership in provoking or mitigating cancers. Biochim Biophys Acta Rev Cancer. 2022;1877:188679.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"6369_CR14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/gutjnl-2016-312742","volume":"67","author":"KH Lim","year":"2018","unstructured":"Lim KH, Park ES, Kim DH, Cho KC, Kim KP, Park YK, et al. Suppression of interferon-mediated anti-HBV response by single CpG methylation in the 5\u2019-UTR of TRIM22. Gut. 2018;67:166\u201378.","journal-title":"Gut"},{"key":"6369_CR15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.bbrc.2015.04.040","volume":"461","author":"M Kato","year":"2015","unstructured":"Kato M, Muromoto R, Togi S, Iwakami M, Kitai Y, Kon S, et al. PML suppresses IL-6-induced STAT3 activation by interfering with STAT3 and HDAC3 interaction. Biochem Biophys Res Commun. 2015;461:366\u201371.","journal-title":"Biochem Biophys Res Commun"},{"key":"6369_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/nature05732","volume":"446","author":"MU Gack","year":"2007","unstructured":"Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature. 2007;446:916\u201320.","journal-title":"Nature"},{"key":"6369_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ccr.2013.11.011","volume":"25","author":"J Hou","year":"2014","unstructured":"Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, Ng IO, et al. Hepatic RIG-I predicts survival and interferon-alpha therapeutic response in hepatocellular carcinoma. Cancer Cell. 2014;25:49\u201363.","journal-title":"Cancer Cell"},{"key":"6369_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2194-9","volume":"11","author":"X Liu","year":"2020","unstructured":"Liu X, Ma F, Liu C, Zhu K, Li W, Xu Y, et al. UBE2O promotes the proliferation, EMT and stemness properties of breast cancer cells through the UBE2O\/AMPKalpha2\/mTORC1-MYC positive feedback loop. Cell Death Dis. 2020;11:10.","journal-title":"Cell Death Dis"},{"key":"6369_CR19","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.2147\/OTT.S253861","volume":"13","author":"X Chen","year":"2020","unstructured":"Chen X, Zhang S, Liu C, Li G, Lu S, Wang Y, et al. UBE2O promotes progression and epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Onco Targets Ther. 2020;13:6191\u2013202.","journal-title":"Onco Targets Ther"},{"key":"6369_CR20","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41418-020-00616-8","volume":"28","author":"Y Huang","year":"2021","unstructured":"Huang Y, Yang X, Lu Y, Zhao Y, Meng R, Zhang S, et al. UBE2O targets Mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance. Cell Death Differ. 2021;28:671\u201384.","journal-title":"Cell Death Differ"},{"key":"6369_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-017-0499-7","volume":"10","author":"Y Xu","year":"2017","unstructured":"Xu Y, Zhang Z, Li J, Tong J, Cao B, Taylor P, et al. The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis. J Hematol Oncol. 2017;10:132.","journal-title":"J Hematol Oncol"},{"key":"6369_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1126\/science.aan0178","volume":"357","author":"K Yanagitani","year":"2017","unstructured":"Yanagitani K, Juszkiewicz S, Hegde RS. UBE2O is a quality control factor for orphans of multiprotein complexes. Science. 2017;357:472\u20135.","journal-title":"Science"},{"key":"6369_CR23","doi-asserted-by":"publisher","first-page":"eaan0218","DOI":"10.1126\/science.aan0218","volume":"357","author":"AT Nguyen","year":"2017","unstructured":"Nguyen AT, Prado MA, Schmidt PJ, Sendamarai AK, Wilson-Grady JT, Min M, et al. UBE2O remodels the proteome during terminal erythroid differentiation. Science. 2017;357:eaan0218.","journal-title":"Science"},{"key":"6369_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.molcel.2014.03.002","volume":"54","author":"N Mashtalir","year":"2014","unstructured":"Mashtalir N, Daou S, Barbour H, Sen NN, Gagnon J, Hammond-Martel I, et al. Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. Mol Cell. 2014;54:392\u2013406.","journal-title":"Mol Cell"},{"key":"6369_CR25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/cr.2013.21","volume":"23","author":"X Zhang","year":"2013","unstructured":"Zhang X, Zhang J, Zhang L, van Dam H, ten Dijke P. UBE2O negatively regulates TRAF6-mediated NF-kappaB activation by inhibiting TRAF6 polyubiquitination. Cell Res. 2013;23:366\u201377.","journal-title":"Cell Res"},{"key":"6369_CR26","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/emboj.2013.38","volume":"32","author":"X Zhang","year":"2013","unstructured":"Zhang X, Zhang J, Bauer A, Zhang L, Selinger DW, Lu CX, et al. Fine-tuning BMP7 signalling in adipogenesis by UBE2O\/E2-230K-mediated monoubiquitination of SMAD6. EMBO J. 2013;32:996\u20131007.","journal-title":"EMBO J"},{"key":"6369_CR27","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.1038\/s41388-022-02509-1","volume":"41","author":"M Ma","year":"2022","unstructured":"Ma M, Zhang C, Cao R, Tang D, Sang X, Zou S, et al. UBE2O promotes lipid metabolic reprogramming and liver cancer progression by mediating HADHA ubiquitination. Oncogene. 2022;41:5199\u2013213.","journal-title":"Oncogene"},{"key":"6369_CR28","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gkx1041","volume":"46","author":"J Zhou","year":"2018","unstructured":"Zhou J, Xu Y, Lin S, Guo Y, Deng W, Zhang Y, et al. iUUCD 2.0: an update with rich annotations for ubiquitin and ubiquitin-like conjugations. Nucleic Acids Res. 2018;46:D447\u2013D53.","journal-title":"Nucleic Acids Res"},{"key":"6369_CR29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173:400\u201316.e11.","journal-title":"Cell."},{"key":"6369_CR30","doi-asserted-by":"publisher","first-page":"e22930","DOI":"10.1371\/journal.pone.0022930","volume":"6","author":"Z Chen","year":"2011","unstructured":"Chen Z, Chen YZ, Wang XF, Wang C, Yan RX, Zhang Z. Prediction of ubiquitination sites by using the composition of k-spaced amino acid pairs. PLoS One. 2011;6:e22930.","journal-title":"PLoS One"},{"key":"6369_CR31","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.bbapap.2013.04.006","volume":"1834","author":"Z Chen","year":"2013","unstructured":"Chen Z, Zhou Y, Song J, Zhang Z. hCKSAAP_UbSite: improved prediction of human ubiquitination sites by exploiting amino acid pattern and properties. Biochim Biophys Acta. 2013;1834:1461\u20137.","journal-title":"Biochim Biophys Acta"},{"key":"6369_CR32","doi-asserted-by":"publisher","first-page":"bbab574","DOI":"10.1093\/bib\/bbab574","volume":"23","author":"C Wang","year":"2022","unstructured":"Wang C, Tan X, Tang D, Gou Y, Han C, Ning W, et al. GPS-Uber: a hybrid-learning framework for prediction of general and E3-specific lysine ubiquitination sites. Brief Bioinform. 2022;23:bbab574.","journal-title":"Brief Bioinform"},{"key":"6369_CR33","first-page":"e22112","volume":"36","author":"Q Huang","year":"2022","unstructured":"Huang Q, Qin D, Pei D, Vermeulen M, Zhang X. UBE2O and USP7 co-regulate RECQL4 ubiquitinylation and homologous recombination-mediated DNA repair. FASEB J. 2022;36:e22112.","journal-title":"FASEB J"},{"key":"6369_CR34","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ccell.2017.01.003","volume":"31","author":"IK Vila","year":"2017","unstructured":"Vila IK, Yao Y, Kim G, Xia W, Kim H, Kim SJ, et al. A UBE2O-AMPKalpha2 axis that promotes tumor initiation and progression offers opportunities for therapy. Cancer Cell. 2017;31:208\u201324.","journal-title":"Cancer Cell"},{"key":"6369_CR35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41590-019-0323-3","volume":"20","author":"P Hubel","year":"2019","unstructured":"Hubel P, Urban C, Bergant V, Schneider WM, Knauer B, Stukalov A, et al. A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape. Nat Immunol. 2019;20:493\u2013502.","journal-title":"Nat Immunol"},{"key":"6369_CR36","doi-asserted-by":"publisher","first-page":"e0282921","DOI":"10.1128\/mBio.02829-21","volume":"12","author":"A Chikhalya","year":"2021","unstructured":"Chikhalya A, Dittmann M, Zheng Y, Sohn SY, Rice CM, Hearing P. Human IFIT3 protein induces interferon signaling and inhibits adenovirus immediate early gene expression. mBio. 2021;12:e0282921.","journal-title":"mBio"},{"key":"6369_CR37","doi-asserted-by":"publisher","first-page":"e0155722","DOI":"10.1128\/spectrum.01557-22","volume":"10","author":"S Xu","year":"2022","unstructured":"Xu S, Huang J, Xun Z, Li S, Fu Y, Lin N, et al. IFIT3 is increased in serum from patients with chronic hepatitis B virus (HBV) infection and promotes the anti-HBV effect of interferon alpha via JAK-STAT2 in vitro. Microbiol Spectr. 2022;10:e0155722.","journal-title":"Microbiol Spectr"},{"key":"6369_CR38","doi-asserted-by":"crossref","unstructured":"Zhang W, Li Y, Xin S, Yang L, Jiang M, Xin Y, et al. The emerging roles of IFIT3 in antiviral innate immunity and cellular biology. J Med Virol. 2022;88:e28259.","DOI":"10.1002\/jmv.28259"},{"key":"6369_CR39","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/emboj.2012.354","volume":"32","author":"JA Nathan","year":"2013","unstructured":"Nathan JA, Kim HT, Ting L, Gygi SP, Goldberg AL. Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes? EMBO J. 2013;32:552\u201365.","journal-title":"EMBO J"},{"key":"6369_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.335","volume":"11","author":"X Zhang","year":"2021","unstructured":"Zhang X, Hu B, Sun YF, Huang XW, Cheng JW, Huang A, et al. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF\/JAK1\/STAT3 and NF-kB signaling pathways synergistically. Clin Transl Med. 2021;11:e335.","journal-title":"Clin Transl Med"},{"key":"6369_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s13046-018-1005-y","volume":"37","author":"Y Qiu","year":"2018","unstructured":"Qiu Y, Dai Y, Zhang C, Yang Y, Jin M, Shan W, et al. Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3eta\/NF-kappaB feedback loop. J Exp Clin Cancer Res. 2018;37:321.","journal-title":"J Exp Clin Cancer Res"},{"key":"6369_CR42","doi-asserted-by":"publisher","first-page":"e20201268","DOI":"10.1084\/jem.20201268","volume":"218","author":"T Dagher","year":"2021","unstructured":"Dagher T, Maslah N, Edmond V, Cassinat B, Vainchenker W, Giraudier S, et al. JAK2V617F myeloproliferative neoplasm eradication by a novel interferon\/arsenic therapy involves PML. J Exp Med. 2021;218:e20201268.","journal-title":"J Exp Med"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06369-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06369-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06369-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T17:03:36Z","timestamp":1703178216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06369-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6369"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06369-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"assertion":[{"value":"30 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by The First Affiliated Hospital of USTC, and the study was conducted in agreement with the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"854"}}